Phytic acid-based ternary complex bionic NANO material, and preparation method and use thereof
Through the combination of phytic acid, metal ions and protein/polypeptide, a ternary complex biomimetic nanomaterial with high biocompatibility is formed, which solves the problems of insufficient residence time and poor biocompatibility of existing nanomaterials in tumor sites, and achieves the Long-term retention and effective treatment effects.
Patent Information
- Application Number
- PCT/CN2024/107540
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-28
AI Technical Summary
The existing bionic nanomaterials have insufficient residence time in the tumor site and poor biocompatibility, resulting in unsatisfactory treatment results and safety problems.
Using ternary complex biomimicry nanomaterials based on phytic acid, metal ions and proteins/polypeptides, metal cations are used as bridges to form nanomaterials with high biocompatibleness, realizing tumor targeting and long-term Stay.
It has achieved long-term retention in the tumor site, reduced drug toxicity, enhanced therapeutic effect and imaging monitoring capabilities, and has good biocompatibility and clinical transformation value.
Smart Images

Figure CN2024107540_28112024_PF_FP_ABST
Abstract
Description
Phytic acid-based ternary composite biomimetic nanomaterial and its preparation method and application
[0001] This application claims priority to the Chinese patent application filed with the China Patent Office on May 25, 2023, with application number 202310595063.5 and application name “Phytic acid-based ternary complex biomimetic nanomaterials, preparation methods and applications thereof”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present application relates to the preparation of a nanomaterial, and in particular to the preparation and application of a ternary complex biomimetic nanomaterial based on phytic acid. Background Art
[0003] As cancer treatment gradually enters the era of "precision medicine," the delivery of imaging and therapeutic drugs via biomimetic nanomaterials holds broad promise for accurate tumor diagnosis and treatment. However, insufficient tumor accumulation time and poor biocompatibility are major limitations hindering the further development and clinical translation of biomimetic nanomaterials. While targeted molecular modification and the construction of stimuli-responsive probes can enhance the accumulation of nanoparticles in tumors, prolong tumor retention, and improve therapeutic efficacy, the retention time of these nanoparticles in tumors remains unsatisfactory because they can reenter the bloodstream or diffuse into surrounding tissues, preventing long-term and real-time tumor monitoring and treatment. Furthermore, their suboptimal biocompatibility results in drug retention in the body, potentially leading to long-term toxicity. Therefore, the development of biocompatible therapeutic probes that can reside at the tumor site for a long time is essential to overcome these temporal and spatial limitations and achieve precise treatment and tumor monitoring.
[0004] Phytic acid (PA), a type of vitamin B, also known as inositol hexaphosphate, is widely found in plants such as legumes, cereals, dried fruits, vegetables, and fruits. It is also present in most mammalian cells, making it highly biocompatible. Phytic acid is an inositol hexaphosphate ester with an asymmetric six-carbon ring structure. Its molecular structure contains six phosphates and twelve hydroxyl groups, giving it strong chelating properties. PA also exhibits inherent anti-cancer properties, inhibiting the growth of various cancer cells, including leukemia, prostate cancer, breast cancer, liver cancer, colon cancer, and skin cancer.
[0005] Phytic acid has a strong chelating property due to its molecular structure. It is negatively charged in a wide range of pH values and can bind to positively charged Mg. 2+ 、Fe 2+ 、Cd 2+Phytates are complexes formed by the chelation of many divalent or polyvalent metal ions, such as phytates, to form low-solubility complexes. Some phytates have extensive biomedical applications, such as technetium [99mTc] phytate injection, which serves as a PET contrast agent for liver, spleen, and bone marrow imaging. However, low solubility limits the further application of phytates in biomedicine.
[0006] Summary of the Invention
[0007] The biomimetic nanomaterials constructed in the prior art have poor biocompatibility, insufficient accumulation time, and safety issues associated with the accumulation of nanomaterials in the body. This application provides a biomimetic nanomaterial that is highly biocompatible, possesses multiple biological functions such as tumor targeting, treatment, and magnetic resonance imaging, and can maintain a long retention time at the tumor site. This biomimetic nanomaterial can be used to simultaneously deliver continuous radiotherapy and chemotherapy to a tumor while providing long-term imaging monitoring of the therapeutic changes of the tumor.
[0008] In order to solve the above technical problems, the present application proposes a ternary complex biomimetic nanomaterial based on phytic acid, which is a ternary complex composed of phytic acid, metal ions and proteins / polypeptides, wherein the molar ratio of phytic acid to metal ions is 1:(1-6), and the molar ratio of protein / polypeptide to phytic acid is 1:25; the ternary complex is formed by connecting the protein / polypeptide and phytic acid with metal cations as cationic bridges.
[0009] Furthermore, the phytic acid-based ternary composite biomimetic nanomaterial described in the present application, wherein:
[0010] The metal ions are multivalent metal cations.
[0011] The protein / polypeptide is a negatively charged protein / polypeptide at a pH value of 7-10.
[0012] The selection of the multivalent metal cations includes several situations as shown in Table 1.
[0013] Table 1 Selection of polyvalent metal cations for different imaging and therapeutic applications
[0014] At the same time, the present application also provides two preparation methods of the above-mentioned phytic acid-based ternary composite biomimetic nanomaterial.
[0015] Preparation method 1 comprises the following steps:
[0016] S1-1, mixing phytic acid and a metal ion solution in a molar ratio of phytic acid to metal ion of 1:(1-6), stirring uniformly to obtain a mixed solution A;
[0017] S1-2, adding the protein / polypeptide solution to the mixed solution A at a molar ratio of protein / polypeptide to phytic acid of 1:25, and adjusting the pH of the solution to 7-10 to obtain a mixed solution B;
[0018] S1-3, centrifuging the mixed solution B to remove the precipitate, and repeatedly ultrafiltering / dialyzing the supernatant to obtain a ternary complex solution, which is the biomimetic nanomaterial.
[0019] Preparation method 2 comprises the following steps:
[0020] S2-1, taking a certain amount of phytic acid solution, adjusting the pH value of the phytic acid solution to 7-10, adding the protein / polypeptide solution to the pH-adjusted phytic acid solution according to a molar ratio of protein / polypeptide to phytic acid of 1:25, and stirring uniformly to obtain a mixed solution C;
[0021] S2-2, adding a metal ion solution to the mixed solution C at a molar ratio of metal ions to phytic acid of 3:1, and stirring uniformly to obtain a mixed solution D; the metal ions in the metal ion solution are metal ions that can produce precipitation after mixing with the phytic acid solution;
[0022] S2-3, centrifuging the mixed solution D to remove the precipitate, and repeatedly ultrafiltering / dialyzing the supernatant to obtain a ternary complex solution, which is the biomimetic nanomaterial.
[0023] The main factor to be considered in selecting preparation method 1 or preparation method 2 is whether precipitation occurs when the selected metal ion solution and phytic acid solution are mixed at a molar ratio of phytic acid to metal ion of 1:(1-6); if precipitation does not occur, either preparation method 1 or preparation method 2 can be used; if precipitation occurs, preparation method 2 is selected.
[0024] Furthermore, in the above preparation method 2, the metal ion is preferably Gd 3+ 、Bi 3+ and 223 Ra 2+ One or more of .
[0025] In the present application, it is also proposed that the above-mentioned phytic acid-based ternary complex biomimetic nanomaterial can be used to prepare one or more imaging contrast agents of MRI imaging, CT imaging, radionuclide imaging and optical imaging, and to prepare drugs for chemotherapy, radiotherapy or photothermal therapy, wherein the selection of the polyvalent metal cations is shown in Table 1.
[0026] Compared with the prior art, the present invention has the following advantages:
[0027] This application proposes a construction strategy for a multifunctional biomimetic nanomaterial based on phytic acid. After food is ingested by the human body, under the alkaline conditions of the intestine, both protein and phytic acid are negatively charged. At this time, a phytic acid-metal cation-protein ternary complex can be generated with metal cations as bridges. The addition of protein can make the complex have good biocompatibility, biodegradability, low antigenicity, high stability and drug loading. This application simulates the formation of a ternary complex in the intestine. The biomimetic synthesis of the ternary complex biomimetic nanomaterial not only has the characteristics of high biocompatibility, but also has multiple biological functions such as tumor targeting, treatment, and magnetic resonance. The biomimetic nanomaterial prepared can be reassembled in situ at the tumor site to maintain a long residence time to achieve long-term MRI imaging monitoring and radiotherapy of the tumor. And the biomimetic nanomaterial has excellent biocompatibility, can significantly reduce the toxicity of radiotherapy drugs, and has good clinical translation value. In addition, the preparation method of the biomimetic nanomaterial is simple and easy to operate, low cost, and easy to achieve industrial production. It is expected to be used as a new type of nano-diagnosis and treatment probe in the biomedical field. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] FIG1 is a diagram showing the construction principle of the phytic acid ternary complex biomimetic nanomaterial of the present application.
[0029] FIG2 is a transmission electron micrograph of PA-Mn-BSA (PA:Mn=1:3) prepared in Example 1.
[0030] FIG3 is a transmission electron micrograph of PA-Gd-BSA prepared in Example 2.
[0031] FIG4 is a transmission electron micrograph of PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) prepared in Example 4.
[0032] FIG5 is a physical image and a hydrated particle size image of PA-Bi-BSA prepared in Example 3.
[0033] Figure 6 is the PA-Mn / 223 Actual image and hydrated particle size diagram of Ra-BSA.
[0034] FIG7 is a physical image and hydrated particle size image of PA-Mn / Pt-RGD prepared in Example 6.
[0035] FIG8 shows in vitro magnetic resonance imaging of PA-Mn-BSA (PA:Mn=1:3) and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) prepared in Examples 1 and 4.
[0036] FIG9 is an in vitro magnetic resonance imaging of PA-Gd-BSA prepared in Example 2.
[0037] Figure 10 is the PA-Mn / 223 In vitro magnetic resonance imaging of Ra-BSA.
[0038] FIG11 is an in vitro magnetic resonance imaging of PA-Mn / Pt-RGD prepared in Example 6.
[0039] FIG12 is an in vitro CT image of PA-Bi-BSA prepared in Example 3.
[0040] Figure 13 shows the particle size stability of PA-Mn-BSA (PA:Mn=1:3) and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) prepared in Examples 1 and 4 in PBS and FBS, respectively.
[0041] Figure 14 is the acidic environment reassembly response of PA-Mn-BSA (PA:Mn=1:3) prepared in Example 1, wherein (a) is a physical image of the PA-Mn-BSA (PA:Mn=1:3) at pH 7.4 and 5.0, (b) is the particle size change of the PA-Mn-BSA (PA:Mn=1:3) at pH 7.4 and 5.0, and (c) is a transmission electron microscopy image of the PA-Mn-BSA (PA:Mn=1:3) at pH 5.0.
[0042] Figure 15 shows the killing effects of PA-Mn-BSA (PA:Mn=1:3) of Example 1, PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) of Example 4, and the chemotherapy drug cisplatin CDDP on prostate cancer PC-3 cells.
[0043] Figure 16 PA-Mn / 223 The killing effect of Ra-BSA on prostate cancer PC-3 cells.
[0044] FIG17 shows the killing effect of PA-Mn / Pt-RGD of Example 6 on prostate cancer PC-3 cells.
[0045] Figure 18 shows the in vivo magnetic resonance imaging effects of PA-Mn-BSA (PA:Mn=1:3) of Example 1 and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) of Example 4, wherein (a) is the in vivo magnetic resonance imaging effect of PA-Mn-BSA (PA:Mn=1:3), and (b) is the in vivo magnetic resonance imaging effect of PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2).
[0046] Figure 19 shows the in vivo tumor inhibition effects of the four drugs, wherein (a) is an anatomical diagram of the tumor in PC-3 tumor-bearing mice treated with PBS, PA-Mn-BSA (PA:Mn=1:3) of Example 1, CDDP, and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) of Example 4 for 14 days, and (b) is a growth curve of the tumor in PC-3 tumor-bearing mice treated with PBS, PA-Mn-BSA (PA:Mn=1:3) of Example 1, CDDP, and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) of Example 4.
[0047] FIG20 is a comparison of the Pt content in the tumor after 14 days of treatment with CDDP and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) of Example 4.
[0048] Figure 21 is a PC-3 tumor-bearing mouse with PBS, PA-Mn-BSA (PA:Mn = 1:3) of Example 1, 223 RaCl2, PA-Mn / 223 Anatomical images of tumors after 10 days of Ra-BSA treatment.
[0049] Figure 22 is the biochemical analysis of mice after injection of PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) of Example 4, wherein (a) is aspartate aminotransferase (AST), (b) is alanine aminotransferase (ALT), (c) is urea nitrogen (BUN), and (d) is blood creatinine (CRE). DETAILED DESCRIPTION
[0050] The design idea of a method for preparing a bionic nanomaterial proposed in this application is to adopt a biomimetic synthesis strategy to prepare highly biocompatible multifunctional biomimetic nanomaterials for use in the biomedical field. The biomimetic nanomaterial can be coordinated and loaded with a variety of imaging / therapeutic drugs to meet the requirements of various biomedical applications. The preparation method of this application is to simulate the formation of a phytic acid ternary complex in the intestine, and use various metal ions such as manganese and gadolinium as bridges to biomimetically synthesize phytic acid ternary complexes of different protein / polypeptide bases to construct a highly biocompatible nano-diagnostic and therapeutic probe that can achieve long-term aggregation at the tumor site and has multiple functions such as tumor imaging and treatment. It is expected to be used as a new type of biomimetic nanomaterial in the biomedical field. At the same time, the preparation process of the diagnostic and therapeutic agent of this application is simple and easy to achieve industrial production.
[0051] The present application will be further described below with reference to the accompanying drawings and specific embodiments, but the following embodiments are by no means intended to limit the present application in any way.
[0052] In this application, the biomimetic nanomaterials mentioned refer to synthesized materials that are nanoparticles and can be used for imaging, treatment or integrated diagnosis and treatment of tumors.
[0053] The biomimetic nanomaterial described in the present application is a phytic acid ternary complex, which comprises phytic acid, metal ions coordinated and chelated with phytic acid, and proteins / polypeptides, wherein the molar ratio of phytic acid to metal ions is 1:(1-6), and the molar ratio of protein / polypeptide to phytic acid is 1:25; the ternary complex is formed by connecting the protein / polypeptide and phytic acid with metal cations as cationic bridges, and is used as a biomimetic nanomaterial for the imaging, diagnosis and treatment of tumors.
[0054] In the biomimetic nanomaterial of the present application, the metal ions are multivalent metal cations. The protein / polypeptide is a protein / polypeptide with a negative charge at a pH of 7 to 10. In the present application, the protein / polypeptide refers to a protein or polypeptide.
[0055] This application provides two methods for preparing the above-mentioned biomimetic nanomaterials, wherein:
[0056] The first method comprises the following steps: mixing phytic acid and a metal ion solution at a molar ratio of phytic acid to metal ions of 1:(1-6), stirring uniformly to obtain a mixed solution A; adding a protein / polypeptide solution to the mixed solution A at a molar ratio of protein / polypeptide to phytic acid of 1:25, and adjusting the pH value of the solution to 7-10 to obtain a mixed solution B; centrifuging the mixed solution B to remove the precipitate, and repeatedly ultrafiltering / dialyzing the supernatant to obtain a ternary complex solution, which is the biomimetic nanomaterial.
[0057] The second method comprises the following steps: taking a certain phytic acid solution, adjusting the pH value of the phytic acid solution to 7-10, adding a protein / polypeptide solution to the phytic acid solution after adjusting the pH value according to a molar ratio of protein / polypeptide to phytic acid of 1:25, stirring evenly, and obtaining a mixed solution C; adding a metal ion solution to the mixed solution C according to a molar ratio of metal ions to phytic acid of 3:1, stirring evenly, and obtaining a mixed solution D; the metal ions in the metal ion solution are metal ions that can produce precipitation after mixing with the phytic acid solution; centrifuging the mixed solution D to remove the precipitate, and repeatedly ultrafiltering / dialyzing the supernatant to obtain a ternary complex solution, which is the biomimetic nanomaterial.
[0058] In the present invention, the ultrafiltration / dialysis refers to ultrafiltration or dialysis.
[0059] In the preparation process of the biomimetic nanomaterial of the present application, the multivalent metal cations include one or more of the elements listed in Table 1. Those skilled in the art can apply them to different imaging and treatment schemes according to the physical and chemical properties of the elements used. Among them, the preferred metal cations for magnetic resonance imaging (MRI) are Fe 2+ 、Fe 3+ 、Mn 2+、Gd 3+ .
[0060] In the preparation process of the biomimetic nanomaterial of the present application, the preferred molar ratio of phytic acid and polyvalent metal cations is 1:3; the protein / polypeptide can be any protein / polypeptide: such as common bovine serum albumin (BSA), human serum albumin (HSA), targeted protein transferrin (Tf), phycocyanin with photothermal properties, targeting peptide RGD, etc.
[0061] In the preparation process of the biomimetic nanomaterial of the present application, the pH is adjusted within a certain value. The pH value is determined based on the isoelectric point of the protein / polypeptide, and its pH range is selected between 7 and 10. For the convenience of biomedical applications, the preferred pH value is 7 to 7.5 within the allowed pH range.
[0062] The biomimetic nanomaterials described herein can be designed with diverse functionalities for use in tumor imaging diagnosis, tumor therapy, and integrated tumor diagnosis and therapy. Applications for tumor imaging include, but are not limited to, the following imaging modalities: MRI, CT, radionuclide imaging, and optical imaging. Applications for tumor therapy include, but are not limited to, the following treatment modalities: chemotherapy, radiotherapy, and photothermal therapy.
[0063] The following examples are provided to further illustrate the present application. It should also be understood that the following examples are only used to further illustrate the present application and are not to be construed as limiting the scope of protection of the present application. Any non-essential improvements and adjustments made by those skilled in the art based on the above content of the present application fall within the scope of protection of the present application.
[0064] The construction of the phytic acid ternary complex biomimetic nanomaterial in the present application is to connect the protein / peptide and phytic acid by using metal cations as bridges to form phytic acid-metal-protein / peptide ternary complex nanoparticles. The principle is shown in Figure 1. When phytic acid coexists with metal cations and protein / peptide, they can form a ternary complex under certain conditions. The formation of the ternary complex is by connecting the negatively charged phytic acid and protein / peptide by using metal cations as cationic bridges.
[0065] Example 1
[0066] (1) According to the method 1, PA-Mn-BSA biomimetic nanomaterials were prepared, and the specific steps are as follows:
[0067] 125 μL of 0.1 M PA solution was added to a reaction vial containing 9 mL of ddH₂O. Then, 125 μL, 250 μL, 375 μL, 500 μL, 625 μL, and 750 μL of 0.1 M MnCl₂ solution were added dropwise at different PA:Mn ratios (1:1, 1:2, 1:3, 1:4, 1:5, and 1:6), respectively, and stirred thoroughly. Then, 500 μL of 1 mM BSA solution was added to the reaction vial, and the pH was quickly adjusted to 7 with 1 M NaOH solution. The mixture was stirred at room temperature for 10 minutes. The solution was collected and centrifuged at 10,000 rpm for 20 minutes. The supernatant was transferred to an ultrafiltration tube and ultrafiltered three times at 4,000 rpm to remove impurities, yielding six PA-Mn-BSA solution samples.
[0068] (2) Relaxation rate determination of PA-Mn-BSA prepared in different ratios
[0069] Screening for optimal phytic acid metal ion ratios (PA:Mn) in phytic acid ternary complexes. Using the six PA-Mn-BSA biomimetic nanomaterials with different PA:Mn ratios as examples, the relaxivity of each PA-Mn-BSA sample was measured to determine the optimal phytic acid metal ion ratio for the constructed phytic acid ternary complex biomimetic nanomaterials for magnetic resonance imaging.
[0070] The bionic nanomaterial samples with different PA:Mn concentrations were placed on the sample holder of a 1.5T nuclear magnetic resonance instrument for T1 value detection. According to the T1 values of samples with different concentrations, a linear regression was performed with concentration (C) as the horizontal axis and T1 value as the vertical axis to construct a fitting curve and calculate the longitudinal relaxation rate (r1) value of each sample.
[0071] The results are shown in Table 2. When the PA:Mn ratio is 1:3, the PA-Mn-BSA nanoparticles exhibit a higher relaxivity and a higher Mn ion loading rate. While a 1:4 ratio exhibits a higher relaxivity, the Mn ion loading efficiency is significantly reduced. Therefore, a 1:3 ratio of PA to metal ions is optimal in the phytic acid ternary complex.
[0072] Table 2 Relaxation rates of PA-Mn-BSA samples with different ratios
[0073] Example 2
[0074] Based on the construction principle of phytic acid ternary complex biomimetic nanomaterials shown in Figure 1, paramagnetic material Gd 3+ It acts as a cationic bridge to connect protein and phytic acid to form PA-Gd-BSA ternary complex nanoparticles.
[0075] PA-Gd-BSA nanoprobes were prepared according to the procedures of Method 2. Specifically, 125 μL of 0.1 M PA solution was added to a reaction flask containing 9 mL of ddHO. The pH of the solution was adjusted to 7 with 1 M NaOH solution. 500 μL of 1 mM BSA solution was then added dropwise to the flask. The mixture was stirred at room temperature for 10 minutes. The solution was collected and centrifuged at 10,000 rpm for 20 minutes. The supernatant was collected and ultrafiltered three times at 4,000 rpm to remove impurities, yielding a PA-Gd-BSA solution.
[0076] Example 3
[0077] Based on the construction principle of biomimetic nanomaterials described in FIG1 , high atomic number bismuth ions are used as cationic bridges to connect protein and phytic acid to form phytic acid-bismuth-protein ternary complex nanoparticles.
[0078] PA-Bi-BSA biomimetic nanomaterials were prepared according to the steps of Method 2. Specifically, 125 μL of 0.1 M PA solution was added to a reaction flask containing 9 mL of ddH2O. The pH of the solution was adjusted to 7 with 1 M NaOH solution. 500 μL of 1 mM BSA solution was then added dropwise to the reaction flask. The mixture was stirred at room temperature for 10 minutes. The solution was collected and centrifuged at 10,000 rpm for 20 minutes. The supernatant was collected and ultrafiltered three times at 4,000 rpm to remove impurities, yielding a PA-Bi-BSA solution.
[0079] Example 4
[0080] (1) Based on the preparation principle diagram in Figure 1, this example uses paramagnetic manganese ions and the chemotherapeutic drug cisplatin as examples to prepare PA-Mn / Pt-BSA biomimetic nanomaterials according to the steps of Method 1. The optimal synthesis ratio was screened by setting different ratios of PA:metal ions. The specific steps are as follows: 125 μL of 0.1M PA solution is added to a reaction bottle containing 9 ml of ddH2O, and then 125 μL, 187.5 μL, and 250 μL of 0.1M MnCl2 solution and 250 μL, 187.5 μL, and 125 μL of 0.1M cis-diaminedihydrate platinum (II) solution are added dropwise according to different molar ratios of PA:Mn:Pt, including PA:Mn:Pt of 1:1:2, 1:1.5:1.5, and 1:2:1, respectively, and stirred evenly; then 500 μL of 1 mM BSA solution is added to the reaction bottle, and the pH of the solution is quickly adjusted to 7 with 1M NaOH solution, and stirred at room temperature for 10 minutes. The solution was collected and centrifuged at 10,000 rpm for 20 minutes. The supernatant was placed in an ultrafiltration tube and ultrafiltered three times at 4,000 rpm to remove impurities, thereby obtaining six PA-Mn / Pt-BSA solution samples.
[0081] (2) Relaxation rate determination of PA-Mn / Pt-BSA prepared in different ratios
[0082] The optimal metal ion ratio in PA-Mn / Pt-BSA was screened for magnetic resonance imaging monitoring. Six PA-Mn / Pt-BSA biomimetic nanomaterial samples with varying PA:metal ion ratios were prepared as examples. The relaxivity of each PA-Mn / Pt-BSA sample was measured to determine the optimal metal ion ratio for the constructed phytic acid ternary complex biomimetic nanomaterial for magnetic resonance imaging.
[0083] Six PA-Mn / Pt-BSA biomimetic nanomaterial samples were placed on the sample holder of a 1.5T nuclear magnetic resonance instrument for T1 value detection. According to the T1 value of the proportioned samples, a linear regression was performed with concentration (C) as the horizontal axis and T1 value as the vertical axis to construct a fitting curve and calculate the longitudinal relaxation rate (r1) value of each sample.
[0084] The results are shown in Table 3. Under the condition of ensuring a certain Mn ion loading rate, the PA-Mn / Pt-BSA nanoparticles obtained with a ratio of PA:Mn:Pt = 1:1:2 have a higher relaxivity (11.88) than other ratios. Therefore, the ratio of PA:Mn:Pt in the PA-Mn / Pt-BSA ternary complex is better at 1:1:2.
[0085] Table 3 Relaxation rates of PA-Mn / Pt-BSA samples with different ratios
[0086] Example 5
[0087] Based on the preparation principle diagram of Figure 1, this embodiment takes paramagnetic manganese ions and radiotherapy drug radium chloride as an example, and prepares PA-Mn / according to the steps of the second method. 223 The specific steps are as follows: add 125 μL of 0.1M PA solution to a reaction bottle containing 9ml ddH2O, adjust the pH of the solution to 7 with 1M NaOH solution, add 500 μL of 1mM BSA solution to the reaction bottle, and then add 375 μL of 0.1M MnCl2 solution and 250 μL of radioactive 1Mkq / ml dropwise. 223 RaCl2 solution was stirred at room temperature for 10 minutes. The solution was collected and centrifuged at 10000 rpm for 20 minutes. The supernatant was placed in an ultrafiltration tube and ultrafiltered three times at 4000 rpm to remove impurities and obtain PA-Mn / 223 Ra-BSA solution.
[0088] Example 6
[0089] Based on the preparation principle diagram in Figure 1, the PA-Mn / Pt-RGD biomimetic nanomaterial was prepared according to Method 2, using the peptide RGD as a carrier, carrying paramagnetic manganese ions and the chemotherapeutic drug cisplatin (CDDP). The specific steps are as follows: 125 μL of a 0.1 M PA solution was added to a reaction flask containing 9 mL of ddH₂O. The pH of the solution was adjusted to 10 with a 1 M NaOH solution. 500 μL of a 1 mM RGD solution was then added dropwise to the reaction flask. Then, 125 μL of a 0.1 M MnCl₂ solution and 250 μL of a 0.1 M cisplatin (II) diamine dihydrate solution were added dropwise. The reaction was stirred at room temperature for 10 minutes. The solution was collected and centrifuged at 10,000 rpm for 20 minutes. The supernatant was collected and ultrafiltered three times at 4,000 rpm to remove impurities, yielding a PA-Mn / Pt-RGD solution.
[0090] Test Case
[0091] Characterization of the phytic acid ternary complex prepared in this application and verification of its in vitro and in vivo diagnostic and therapeutic effects
[0092] (1) Transmission electron microscopy examination of the particle size and morphology of the phytic acid ternary complex
[0093] The morphology of the phytic acid ternary complex was observed by transmission electron microscopy using the PA-Mn-BSA (PA:Mn = 1:3) prepared in Example 1, the PA-Gd-BSA prepared in Example 2, and the PA-Mn / Pt-BSA (PA:Mn:Pt = 1:1:2) prepared in Example 4. The solution was diluted to an appropriate concentration and titrated onto a carbon grid. The morphology and particle size of the PA-Mn-BSA, PA-Gd-BSA, and PA-Mn / Pt-BSA nanoparticles were observed under a transmission electron microscope. The results are shown in Figures 2, 3, and 4, respectively. All three phytic acid ternary complex biomimetic nanomaterials have small particle sizes of approximately 10 nm, are relatively uniform, and have good dispersion.
[0094] (2) Dynamic light scattering detection of particle size monitoring of phytic acid ternary complex
[0095] The phytic acid ternary composite biomimetic nanomaterials PA-Bi-BSA, PA-Mn / 223 The hydrated particle size of Ra-BSA and PA-Mn / Pt-RGD was characterized and their particle size was observed. The solution was diluted to an appropriate concentration and placed under a Malvern particle size detector to measure the hydrated particle size of the biomimetic nanomaterials. The results are shown in Figures 5, 6, and 7. 223 Ra-BSA and PA-Mn / Pt-RGD biomimetic nanomaterials are clear and transparent solutions, which indicates that they have good solubility. The particle sizes of the three materials are all in line with the normal distribution. The particle size of PA-Bi-BSA is about 80nm, and that of PA-Mn / 223 The particle size of Ra-BSA is about 27 nm, and the particle size of PA-Mn / Pt-RGD is about 8 nm. Both particle sizes are small and meet the requirements of bionanomedicine applications.
[0096] (3) In vitro MRI imaging effect
[0097] PA-Mn-BSA (PA:Mn=1:3), PA-Gd-BSA, PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2), PA-Mn / 223 Ra-BSA and PA-Mn / Pt-RGD were used as examples to verify the in vitro magnetic resonance imaging effect of single metal or multi-metal phytic acid ternary complexes. The ternary complex solutions were diluted to different concentrations and placed under GE 3.0T magnetic resonance imaging for T1WI imaging. The results showed that PA-Mn-BSA (Figure 8), PA-Mn / Pt-BSA (Figure 8), PA-Gd-BSA (Figure 9), PA-Mn / 223As the concentration of Ra-BSA (Figure 10) and PA-Mn / Pt-RGD (Figure 11) solutions increases, their T1WI signals gradually increase, ultimately displaying extremely high brightness on the T1WI images. Comparison of the magnetic resonance images of PA-Mn-BSA and PA-Mn / Pt-BSA in Figure 8 shows that the MRI performance of PA-Mn-BSA and PA-Mn / Pt-BSA is essentially similar, indicating that the effect of doping with the imaging metal ion Mn and the therapeutic metal Pt on the MRI performance of Mn is negligible. These results demonstrate that phytic acid ternary complex biomimetic nanomaterials, whether prepared with a single metal ion or multiple metal ions, can exhibit excellent T1 imaging performance in vitro.
[0098] (4) In vitro CT imaging effect of phytic acid ternary complex
[0099] To demonstrate that phytic acid ternary complexes prepared with metal ions imaged in other ways also have good imaging effects, such as bismuth, which has a high atomic number and can be used for CT imaging, the PA-Bi-BSA prepared in Example 3 was used as an example for verification. PA-Bi-BSA solutions were prepared at different concentrations and placed under a 64-row CT scan for CT imaging: 100kev, 90ms. The results are shown in Figure 12. As the concentration increases, the brightness of the PA-Bi-BSA solution gradually increases, with a higher brightness at a concentration of 12mg / mL, demonstrating good CT imaging effects. This indicates that the prepared PA-Bi-BSA solution has the potential to be used as a CT contrast agent, and also provides a reference for the preparation of phytic acid ternary complex biomimetic nanomaterials using a variety of other imaging metal ions.
[0100] (5) Stability of phytic acid ternary complex biomimetic nanomaterials
[0101] To demonstrate the stability of the phytic acid ternary complex biomimetic nanomaterial, the particle size changes of the biomimetic nanomaterials in different environments (PBS and FBS) were examined using PA-Mn-BSA (PA:Mn = 1:3) and PA-Mn / Pt-BSA (PA:Mn:Pt = 1:1:2) prepared in Examples 1 and 4. PA-Mn-BSA and PA-Mn / Pt-BSA nanoparticles were placed in PBS and FBS solutions, respectively. The turbidity of the solutions was observed at different time points (30 min, 4 h, 8 h, 1 d, 3 d, 7 d, and 14 d), and their hydrated particle size was measured using a dynamic light scattering particle size analyzer. As shown in Figure 13, the particle size of the PA-Mn-BSA and PA-Mn / Pt-BSA nanoparticles did not change significantly over 14 days in the PBS and FBS environments, demonstrating good stability.
[0102] (6) pH-responsive reassembly properties of phytic acid ternary complexes
[0103] Using PA-Mn-BSA (PA:Mn = 1:3) prepared in Example 1 as an example for verification, the pH was adjusted to 7.4 and 5.0, based on the physiological pH of the human body (7.4) and the pH of tumor cell endosomes (5.0). The changes in the particle size of the nanoparticles at different pH levels were observed using a particle size analyzer. The results showed that when the pH was adjusted from 7.4 to 5.0, the solution changed significantly from clear to turbid, as shown in Figure 14(a), and the particle size showed an explosive growth, as shown in Figure 14(b). Transmission electron microscopy of the nanoparticles at pH 5.0 was also used, as shown in Figure 14(c). Compared with PA-Mn-BSA (PA:Mn = 1:3) at physiological pH (Figure 2), the ternary complex PA-Mn-BSA showed significant aggregation at pH 5.0, demonstrating pH-responsive reassembly capability. This indicates that under the acidic conditions of the tumor, the nano-diagnostic and therapeutic probe can undergo pH-responsive aggregation, which will prevent it from re-entering the blood circulation, thereby increasing the aggregation and retention of nanoparticles at the tumor site, achieving long-term effective retention at the tumor site, and continuous imaging monitoring and treatment of the tumor.
[0104] (7) Inhibition rate of tumor cell growth
[0105] 1) The growth inhibition rate of tumor cells by PA-Mn-BSA and PA-Mn / Pt-BSA biomimetic nanomaterials.
[0106] To demonstrate in vitro that the biomimetic nanomaterials can maintain their antitumor activity and effectively inhibit tumor cell growth after loading them with chemotherapeutic metals via ternary complexes, different concentrations of PA-Mn-BSA (PA:Mn = 1:3) and PA-Mn / Pt-BSA (PA:Mn:Pt = 1:1:2) nanomaterials were co-incubated with PC-3 tumor cells for 72 hours, using cisplatin as a control. Tumor cell survival was assessed using the MTT assay. The results, as shown in Figure 15, show that due to the inherent anticancer effect of phytic acid, as the concentration of PA-Mn-BSA increased, the inhibitory effect was less pronounced. The cell-killing activity of the PA-Mn / Pt-BSA group approached that of the cisplatin group. This indicates that the cisplatin-loaded PA-Mn / Pt-BSA biomimetic nanomaterials maintain the tumor cell-killing effect of cisplatin, providing evidence for their potential use in in vivo tumor therapy and opening the door to the construction of multifunctional phytic acid ternary complex biomimetic nanomaterials.
[0107] 2)PA-Mn / 223 The growth inhibition rate of tumor cells by Ra-BSA biomimetic nanomaterials.
[0108] In order to verify in vitro that after loading radiotherapeutic metals through ternary complexes, biomimetic nanomaterials can still maintain their anti-tumor activity and effectively inhibit the growth of tumor cells. 223 RaCl2 was used as a control, and the PA-Mn / 223 Ra-BSA was co-incubated with PC-3 tumor cells at different radioactivity for 72 hours, and the survival rate of tumor cells was detected by MTT assay. The results are shown in Figure 16: With the increase of radioactivity, PA-Mn / 223 After treatment with Ra-BSA, the proliferation of PC-3 cells was significantly inhibited, and its inhibitory effect on tumor cell growth was similar to that of 223 RaCl2, which indicates that it is loaded with radioactive elements 223 PA-Mn / Ra 223 Ra-BSA maintains 223 The killing effect of Ra on tumor cells provides a basis for the construction of multifunctional phytic acid ternary complex biomimetic nanomaterials.
[0109] 3) The growth inhibition rate of tumor cells by PA-Mn / Pt-RGD bionic nanomaterials.
[0110] In order to confirm in vitro that the ternary complex biomimetic nanomaterial constructed with polypeptide as a carrier can still maintain the anti-tumor activity of the loaded metal drug and can effectively inhibit the growth of tumor cells. The PA-Mn / Pt-RGD biomimetic nanomaterial prepared in Example 6 was incubated with PC-3 tumor cells at different concentrations for 72 hours, and the survival rate of tumor cells was detected by MTT method. The results are shown in Figure 17: as the concentration of PA-Mn / Pt-RGD increases, the growth of tumor cells is significantly inhibited, which indicates that the PA-Mn / Pt-RGD biomimetic nanomaterial loaded with cisplatin retains the killing effect of cisplatin on tumor cells, which provides a basis for constructing multifunctional phytic acid ternary complex biomimetic nanomaterials by polypeptides.
[0111] (8) In vivo tumor imaging monitoring
[0112] In vivo tumor imaging monitoring using PA-Mn-BSA and PA-Mn / Pt-BSA biomimetic nanomaterials
[0113] In order to attempt to confirm that the phytic acid ternary complex biomimetic nanomaterial of the present application can achieve excellent imaging effects at the in vivo level when loaded with imaging metal ions, this example uses PA-Mn-BSA (PA:Mn=1:3) and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) prepared in Examples 1 and 4 as examples to verify their in vivo magnetic resonance imaging effects.
[0114] PC-3 tumor-bearing mice were injected with PA-Mn-BSA or PA-Mn / Pt-BSA solutions via the tail vein. Tumors were monitored using a 3.0T MRI scanner with continuous T1-weighted magnetic resonance imaging (MRI) before and at various time points after injection. As shown in Figure 18a, PA-Mn-BSA treatment significantly enhanced the T1-weighted magnetic resonance imaging (TWI) signal at the tumor site of PC-3 tumor-bearing mice. This enhancement continued to increase, reaching a peak at 12 hours. The enhancement was also sustained for a long time, with the enhancement still visible after 14 days. Figure 18b also shows that PA-Mn / Pt-BSA treatment also significantly enhanced the T1-weighted magnetic resonance imaging (TWI) signal at the tumor site of PC-3 tumor-bearing mice. The enhancement pattern was similar to that observed with PA-Mn-BSA treatment, reaching a peak at 12 hours. The signal began to decrease over time, but the enhancement was maintained for a long time. This long-lasting enhancement suggests that the biomimetic nanomaterial can retain its position in the tumor site for a long time. The above results show that both PA-Mn-BSA and PA-Mn / Pt-BSA biomimetic nanomaterials can achieve good magnetic resonance imaging effects in vivo and can achieve long-term enhanced effects during tumor retention. This confirms that the phytic acid ternary complex biomimetic nanomaterial of the present application can achieve imaging, diagnosis and monitoring of living tumors after loading imaging metals; and can be retained at the tumor site for a long time, which is expected to achieve long-term therapeutic effects on tumors to enhance the therapeutic effect of drugs.
[0115] (9) In vivo tumor suppression effect
[0116] 1) In vivo tumor inhibition effect of PA-Mn / Pt-BSA biomimetic nanomaterials
[0117] In order to demonstrate that the biomimetic nanomaterials of the present application can achieve tumor growth inhibition effects at the in vivo level when chelating chemotherapeutic metal ions, the PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) prepared in Example 4 was used as an example to verify its in vivo tumor inhibition effects.
[0118] A PC-3 tumor-bearing mouse model was established. When the tumor grew to 100 mm 3PA-Mn / Pt-BSA solution was injected into the mouse tail vein at 14 days post-injection, with PBS, CDDP, and PA-Mn-BSA (PA:Mn=1:3) prepared in Example 1 used as controls. Tumor size was measured every other day for 14 days after injection to observe the tumor growth inhibition effects of the different groups. Tumors were dissected and analyzed on day 14. The results, as shown in Figure 19 (a), show that compared with the PBS, CDDP, and PA-Mn-BSA groups, the PA-Mn / Pt-BSA group had the smallest tumor volume, demonstrating a strong tumor growth inhibition effect. The PA-Mn-BSA group showed no significant change in tumor volume compared to the PBS group, indicating a weak growth inhibition effect. Although the CDDP group had a smaller tumor volume than the PBS group, its tumor inhibition effect was still inferior to that of the PA-Mn / Pt-BSA group. The tumor growth curve (Figure 19(b)) also shows that after treatment with PA-Mn / Pt-BSA, tumor growth in the PA-Mn / Pt-BSA group slowed, significantly inhibiting tumor growth compared to the exponential growth in the PBS group. These results demonstrate that PA-Mn / Pt-BSA biomimetic nanomaterials, chelated with the therapeutic metal (cisplatin), exhibit a significant growth-inhibiting effect on living tumors. At the same time, on day 14, the tumors of the CDDP group and the PA-Mn / Pt-BSA group were taken and the Pt content therein was detected by ICP-MS. The results are shown in Figure 20. On day 14, the Pt content in the tumor site of the PA-Mn / Pt-BSA group was significantly higher than that of the CDDP treatment group. This is consistent with the magnetic resonance imaging results of PA-Mn-BSA (PA:Mn=1:3) and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) prepared in Examples 1 and 4, indicating that PA-Mn / Pt-BSA can cause the chemotherapy drug cisplatin to accumulate at the tumor site for a long time, thereby achieving a long-term chemotherapy effect.
[0119] 2)PA-Mn / 223 In vivo tumor inhibitory effect of Ra-BSA
[0120] In order to verify that the biomimetic nanomaterials of the present application can achieve tumor growth inhibition effect at the living level when chelating radioactive therapeutic metal ions, the PA-Mn / 223 Ra-BSA was used as an example to verify its in vivo tumor inhibition effect.
[0121] A PC-3 tumor-bearing mouse model was established. When the tumor grew to 100 mm 3 PA-Mn / 223 Ra-BSA solution, PBS, 223RaCl2 and PA-Mn-BSA (PA:Mn=1:3) prepared in Example 1 were used as controls; the tumor size was measured every other day after injection for 10 days to observe the tumor growth inhibition effect of different groups. On the 10th day, the tumors of mice were dissected and their sizes were observed. The results are shown in Figure 21. Compared with PBS, 223 RaCl2, PA-Mn-BSA group, PA-Mn / 223 The Ra-BSA group had the smallest tumor volume and showed a strong tumor growth inhibition effect; 223 Although the tumor volume of the RaCl2 group was smaller than that of the PBS group, its tumor inhibition effect was still not as good as that of the PA-Mn / 223 Ra-BSA group.
[0122] (10) Safety assessment
[0123] Since most chemotherapy drugs have certain toxic side effects, the safety of PA-Mn-BSA (PA:Mn=1:3) and PA-Mn / Pt-BSA (PA:Mn:Pt=1:1:2) prepared in Examples 1 and 4 were evaluated as examples.
[0124] Normal Kunming mice were injected with PBS, CDDP, PA-Mn-BSA, and PA-Mn / Pt-BSA through the tail vein, and blood biochemical analysis was performed 24 hours later. The results are shown in Figure 22. After CDDP treatment, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea nitrogen (BUN), and blood creatinine (CRE) in mice were significantly increased compared with those in the PBS group, showing obvious hepato-renal toxicity. After treatment with PA-Mn-BSA and PA-Mn / Pt-BSA, their blood biochemical indicators showed no significant changes compared with those in the PBS group, and no significant risk of hepato-renal toxicity was shown. The hepato-renal toxicity of mice treated with PA-Mn / Pt-BSA loaded with cisplatin was significantly reduced compared with that of mice treated with free CDDP, which suggests that the phytic acid ternary complex biomimetic nanomaterials of the present application can significantly reduce the toxic and side effects of loaded drugs. The above results show that PA-Mn-BSA and PA-Mn / Pt-BSA have good biosafety, which indicates that the biomimetic nanomaterials constructed by phytic acid ternary complex have high biocompatibility.
[0125] In summary, this application provides a method for preparing a ternary complex biomimetic nanomaterial based on phytic acid. This method addresses the low solubility of phytate and constructs a soluble biomimetic nanomaterial to meet the needs of imaging diagnosis, treatment, and integrated diagnosis and treatment of tumors. The biomimetic nanomaterial prepared by this method has high biocompatibility and can be reassembled in situ in the acidic environment of the tumor to remain at the tumor site for a long time, achieving long-term monitoring and treatment effects.
[0126] It is obvious to those skilled in the art that the present application is not limited to the details of the above exemplary embodiments, and that the present application can be implemented in other specific forms without departing from the spirit or essential features of the present application. Therefore, from any point of view, the embodiments should be regarded as exemplary and non-limiting. Under the guidance of this application, those skilled in the art can make many changes without departing from the purpose of this application, and all of these changes are within the protection of this application.
Claims
1. A ternary composite biomimetic nanomaterial based on phytic acid, characterized in that: The bionic nanomaterial is a ternary complex composed of phytic acid, metal ions and protein / peptide, wherein the molar ratio of phytic acid to metal ions is 1:(1-6), and the molar ratio of protein / peptide to phytic acid is 1:25; the protein / peptide and phytic acid are connected by using metal ions as cationic bridges to form the ternary complex.
2. The phytic acid-based ternary composite biomimetic nanomaterial according to claim 1, characterized in that: The metal ions are multivalent metal cations.
3. The bionic nanomaterial based on phytic acid ternary complex according to claim 1, characterized in that: The protein / polypeptide is a negatively charged protein / polypeptide at a pH value of 7-10.
4. The phytic acid-based ternary composite biomimetic nanomaterial according to claim 2, characterized in that: The selection of the polyvalent metal cation is: When used to prepare a contrast agent for MRI imaging, the multivalent metal cation is selected from Cr 3+ 、Co 2+ , Mn 2+ , Fe 2+ , Fe 3+ , Cu 2+ , Cu 3+ ,La 2+ , Gd 3+ 、Ce 3+ , Tb 3+ , Pr 3+ 、Dy 3+ 、Nd 3+ 、Ho 3+ 、Pm 3+ , Er 3+ 、Sm 3+ 、Tm 3+ 、Eu 3+ , Yb 3+ 、Lu 3+ ; When used to prepare contrast agents for CT imaging, the multivalent metal cation is selected from Yb 3+ 、Lu 3+ 、Bi 2+ , Hf 4+ 、Re 4+ , W 4+ 、 5+ ; When used to prepare a radionuclide imaging contrast agent, the multivalent metal cation is selected from 177 Lu 3+ , 68 Ga 3+ 、99mTc 7+ 、Sm 3+ , 111 In 3+ , 62 Cu 2+ ; When used to prepare contrast agents for optical imaging, the multivalent metal cation is selected from Yb 3+ 、Lu 3+ , Er 3+ 、Nd 3+ ; When used for preparing a chemotherapeutic drug, the polyvalent metal cation is selected from Pt 2+ 、Ru 3+ , Os 2+ ; When used to prepare a drug for radiotherapy, the polyvalent metal cation is selected from 177 Lu 3+ , 223 Ra 2+ , 89 Sr 2+ , 60 Co 2+ , 192 Ir 3+ , 182 Ta 5+ ; When used to prepare a drug for photothermal therapy, the multivalent metal cation is selected from Re 4+ , W 4+ 、Bi 2+ .
5. A method for preparing a ternary composite biomimetic nanomaterial based on phytic acid as claimed in any one of claims 1 to 4, characterized in that: The following steps are involved: S1-1, mixing phytic acid and metal ion solution in a molar ratio of phytic acid to metal ion of 1:(1-6), stirring evenly, to obtain a mixed solution A; S1-2, adding the protein / polypeptide solution to the mixed solution A at a molar ratio of protein / polypeptide to phytic acid of 1:25, and adjusting the pH value of the solution to 7-10 to obtain a mixed solution B; S1-3, centrifuging the mixed solution B to remove the precipitate, and repeatedly ultrafiltering / dialyzing the supernatant to obtain a ternary complex solution, which is the bionic nanomaterial.
6. A method for preparing a ternary composite biomimetic nanomaterial based on phytic acid as claimed in any one of claims 1 to 4, characterized in that: The following steps are involved: S2-1, taking a certain amount of phytic acid solution, adjusting the pH value of the phytic acid solution to 7-10, adding the protein / polypeptide solution to the phytic acid solution after adjusting the pH value according to a molar ratio of protein / polypeptide to phytic acid of 1:25, stirring evenly, to obtain a mixed solution C; S2-2, adding a metal ion solution to the mixed solution C at a molar ratio of metal ions to phytic acid of 3:1, and stirring evenly to obtain a mixed solution D; the metal ions in the metal ion solution are metal ions that can produce precipitation after mixing with the phytic acid solution; S2-3, centrifuging the mixed solution D to remove the precipitate, and repeatedly ultrafiltering / dialyzing the supernatant to obtain a ternary complex solution, which is the bionic nanomaterial.
7. The method for preparing the ternary composite bionic nanomaterial based on phytic acid according to claim 6, characterized in that: The metal ion is Gd 3+ 、Bi 2+ and 223 Ra 2+ One or more of .
8. An application of a ternary composite bionic nanomaterial based on phytic acid, characterized in that: The bionic nanomaterial according to any one of claims 1 to 4 or the bionic nanomaterial prepared according to any one of claims 5 to 7 is used as a contrast agent for one or more of the following imaging methods, the imaging methods including MRI imaging, CT imaging, radionuclide imaging and optical imaging, wherein the metal ion is a multivalent metal cation, and the selection of the multivalent metal cation includes: When used to prepare a contrast agent for MRI imaging, the multivalent metal cation is selected from Cr 3+ 、Co 2+ , Mn 2+ , Fe 2+ , Fe 3+ , Cu 2+ , Cu 3+ ,La 2+ , Gd 3+ 、Ce 3+ , Tb 3+ , Pr 3+ 、Dy 3+ 、Nd 3+ 、Ho 3+ 、Pm 3+ , Er 3+ 、Sm 3+ 、Tm 3+ 、Eu 3+ , Yb 3+ 、Lu 3+ ; When used to prepare contrast agents for CT imaging, the multivalent metal cation is selected from Yb 3+ 、Lu 3+ 、Bi 2+ , Hf 4+ 、Re 4+ , W 4+ 、 5+ ; When used to prepare a radionuclide imaging contrast agent, the multivalent metal cation is selected from 177 Lu 3+ 、68Ga 3+ , 99 mTc 7+ 、Sm 3+ , 111 In 3+ , 62 Cu 2+ ; When used to prepare contrast agents for optical imaging, the multivalent metal cation is selected from Yb 3+ 、Lu 3+ , Er 3+ 、Nd 3+ .
9. An application of a ternary composite bionic nanomaterial based on phytic acid, characterized in that: The bionic nanomaterial according to any one of claims 1 to 4 or the bionic nanomaterial prepared according to any one of claims 5 to 7 is used to prepare drugs for chemotherapy, radiotherapy or photothermal therapy, wherein the metal ion is a multivalent metal cation, and the selection of the multivalent metal cation includes: When used for preparing a chemotherapeutic drug, the polyvalent metal cation is Pt 2+ 、Ru 3+ , Os 2+ ; For preparing a drug for radiotherapy, the multivalent metal cation is selected from 177 Lu 3+ , 223 Ra 3+ , 89 Sr 2+ , 60 Co 2+ , 192 Ir 3+ , 182 Ta 5+ ; When used to prepare a drug for photothermal therapy, the multivalent metal cation is selected from Re 4+ , W 4+ 、Bi 2+ .
Citation Information
Patent Citations
Ternary compound bionic nanomaterial based on phytic acid as well as preparation method and application of ternary compound bionic nanomaterial
CN118557757A
Magnetic resonance imaging contrast agent with paramagnetic-inositol phosphates complexes
CN102548585A
Site-specific, kinetically inert conjugation of labels and / or carriers to target molecules such as his-tagged proteins via metal complex reagents
CN113993548A
